Clinical trial
Vaccine Treatment for Surgically Resected Pancreatic Cancer
NCT00255827 · NewLink Genetics Corporation, Industry · Completed
Key facts
| NCT number | NCT00255827 |
|---|---|
| Title | Vaccine Treatment for Surgically Resected Pancreatic Cancer |
| Official title | A Phase I/II Study of Algenpantucel-L (HyperAcute Pancreas) an Antitumor Vaccination Using Alpha(1,3)Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Pancreatic Cancer |
| Lead sponsor | NewLink Genetics Corporation, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Biological |
| Interventions | HyperAcute-Pancreatic Cancer Vaccine |
| Enrollment | 7 |
| Start date | Nov 1, 2005 |
| Completion | Sep 1, 2007 |
| First posted | Nov 21, 2005 |
| Last update posted | May 28, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: